{"pmid":32391719,"title":"Cardiovascular disease and COVID-19: les liaisons dangereuses.","text":["Cardiovascular disease and COVID-19: les liaisons dangereuses.","Patients with cardiovascular risk factors or established cardiovascular disease have an increased risk of developing coronavirus disease 19 and have a worse outcome when infected, but translating this notion into effective action is challenging. At present it is unclear whether cardiovascular therapies may reduce the likelihood of infection, or improve the survival of infected patients. Given the crucial importance of this issue for clinical cardiologists and all specialists dealing with coronavirus disease 19, we tried to recapitulate the current evidence and provide some practical recommendations.","Eur J Prev Cardiol","Barison, Andrea","Aimo, Alberto","Castiglione, Vincenzo","Arzilli, Chiara","Lupon, Josep","Codina, Pau","Santiago-Vacas, Evelyn","Cediel, German","Emdin, Michele","Bayes-Genis, Antoni","32391719"],"abstract":["Patients with cardiovascular risk factors or established cardiovascular disease have an increased risk of developing coronavirus disease 19 and have a worse outcome when infected, but translating this notion into effective action is challenging. At present it is unclear whether cardiovascular therapies may reduce the likelihood of infection, or improve the survival of infected patients. Given the crucial importance of this issue for clinical cardiologists and all specialists dealing with coronavirus disease 19, we tried to recapitulate the current evidence and provide some practical recommendations."],"journal":"Eur J Prev Cardiol","authors":["Barison, Andrea","Aimo, Alberto","Castiglione, Vincenzo","Arzilli, Chiara","Lupon, Josep","Codina, Pau","Santiago-Vacas, Evelyn","Cediel, German","Emdin, Michele","Bayes-Genis, Antoni"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391719","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1177/2047487320924501","keywords":["covid-19","coronavirus","sars-cov-2","cardiovascular","comorbidities","risk factors"],"topics":["Treatment","Mechanism","Diagnosis","Prevention"],"weight":1,"_version_":1666528580179329024,"score":9.490897,"similar":[{"pmid":32433342,"title":"Cardiovascular Manifestation and Treatment in COVID-19.","text":["Cardiovascular Manifestation and Treatment in COVID-19.","The novel coronavirus disease 2019 (COVID-19), with first presentation of atypical pneumonia, has spread rapidly from Wuhan, China on December 12, 2019 to over 200 countries, caused 2310572 infected individuals and 158691 mortalities, updated on 2020/4/19. Many studies have published timely to help global health-care workers to understand and control the disease. Vulnerable patients with risk factors such as elderly, cardiovascular diseases (e.g. hypertension, coronary disease, or cardiomyopathy), diabetes, chronic kidney disease...etc., have worse outcomes after covid-19 infection. COVID-19 could directly cause cardiovascular injuries such as pericarditis, myocarditis, myocardial infarction, heart failure, arrhythmias or thromboembolic events, which urge cardiologists to be involved in the frontline to practice. Here we provide a review of COVID-19 on cardiovascular system to assist clinical cardiologists to better understand the disease and being capable of providing comprehensive medical support.","J Chin Med Assoc","Su, Yen-Bo","Kuo, Ming-Jen","Lin, Ting-Yu","Chien, Chian-Shiu","Yang, Yi-Ping","Chou, Shih-Jie","Leu, Hsin-Bang","32433342"],"abstract":["The novel coronavirus disease 2019 (COVID-19), with first presentation of atypical pneumonia, has spread rapidly from Wuhan, China on December 12, 2019 to over 200 countries, caused 2310572 infected individuals and 158691 mortalities, updated on 2020/4/19. Many studies have published timely to help global health-care workers to understand and control the disease. Vulnerable patients with risk factors such as elderly, cardiovascular diseases (e.g. hypertension, coronary disease, or cardiomyopathy), diabetes, chronic kidney disease...etc., have worse outcomes after covid-19 infection. COVID-19 could directly cause cardiovascular injuries such as pericarditis, myocarditis, myocardial infarction, heart failure, arrhythmias or thromboembolic events, which urge cardiologists to be involved in the frontline to practice. Here we provide a review of COVID-19 on cardiovascular system to assist clinical cardiologists to better understand the disease and being capable of providing comprehensive medical support."],"journal":"J Chin Med Assoc","authors":["Su, Yen-Bo","Kuo, Ming-Jen","Lin, Ting-Yu","Chien, Chian-Shiu","Yang, Yi-Ping","Chou, Shih-Jie","Leu, Hsin-Bang"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32433342","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1097/JCMA.0000000000000352","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667342288197517314,"score":193.19853},{"pmid":32425199,"pmcid":"PMC7228893","title":"Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.","text":["Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.","Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure and mortality have been reported with the use of these drugs. It is important to have a knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes.","Am J Cardiol","Aggarwal, Gaurav","Henry, Brandon Michael","Aggarwal, Saurabh","Bangalore, Sripal","32425199"],"abstract":["Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure and mortality have been reported with the use of these drugs. It is important to have a knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes."],"journal":"Am J Cardiol","authors":["Aggarwal, Gaurav","Henry, Brandon Michael","Aggarwal, Saurabh","Bangalore, Sripal"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425199","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.amjcard.2020.04.054","keywords":["covid-19","cardiovascular","coronavirus"],"e_drugs":["remdesivir","Azithromycin","lopinavir-ritonavir drug combination"],"topics":["Treatment"],"weight":1,"_version_":1667352728822611970,"score":161.44008},{"pmid":32403242,"title":"Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review.","text":["Prognostic Value of Cardiovascular Biomarkers in COVID-19: A Review.","In early December 2019, the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in Wuhan, China. As of May 10th, 2020, a total of over 4 million COVID-19 cases and 280,000 deaths have been reported globally, reflecting the raised infectivity and severity of this virus. Amongst hospitalised COVID-19 patients, there is a high prevalence of established cardiovascular disease (CVD). There is evidence showing that COVID-19 may exacerbate cardiovascular risk factors and preexisting CVD or may lead to cardiovascular complications. With intensive care units operating at maximum capacity and such staggering mortality rates reported, it is imperative during this time-sensitive COVID-19 outbreak to identify patients with an increased risk of adverse outcomes and/or myocardial injury. Preliminary findings from COVID-19 studies have shown the association of biomarkers of acute cardiac injury and coagulation with worse prognosis. While these biomarkers are recognised for CVD, there is emerging prospect that they may aid prognosis in COVID-19, especially in patients with cardiovascular comorbidities or risk factors that predispose to worse outcomes. Consequently, the aim of this review is to identify cardiovascular prognostic factors associated with morbidity and mortality in COVID-19 and to highlight considerations for incorporating laboratory testing of biomarkers of cardiovascular performance in COVID-19 to optimise outcomes.","Viruses","Aboughdir, Maryam","Kirwin, Thomas","Abdul Khader, Ashiq","Wang, Brian","32403242"],"abstract":["In early December 2019, the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in Wuhan, China. As of May 10th, 2020, a total of over 4 million COVID-19 cases and 280,000 deaths have been reported globally, reflecting the raised infectivity and severity of this virus. Amongst hospitalised COVID-19 patients, there is a high prevalence of established cardiovascular disease (CVD). There is evidence showing that COVID-19 may exacerbate cardiovascular risk factors and preexisting CVD or may lead to cardiovascular complications. With intensive care units operating at maximum capacity and such staggering mortality rates reported, it is imperative during this time-sensitive COVID-19 outbreak to identify patients with an increased risk of adverse outcomes and/or myocardial injury. Preliminary findings from COVID-19 studies have shown the association of biomarkers of acute cardiac injury and coagulation with worse prognosis. While these biomarkers are recognised for CVD, there is emerging prospect that they may aid prognosis in COVID-19, especially in patients with cardiovascular comorbidities or risk factors that predispose to worse outcomes. Consequently, the aim of this review is to identify cardiovascular prognostic factors associated with morbidity and mortality in COVID-19 and to highlight considerations for incorporating laboratory testing of biomarkers of cardiovascular performance in COVID-19 to optimise outcomes."],"journal":"Viruses","authors":["Aboughdir, Maryam","Kirwin, Thomas","Abdul Khader, Ashiq","Wang, Brian"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32403242","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/v12050527","keywords":["covid-19","sars-cov-2","cardiovascular disease","coronavirus"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666950579832750080,"score":153.53162},{"pmid":32462267,"title":"Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation.","text":["Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation.","Coronavirus diseases 2019 (COVID-19) has become a worldwide pandemic affecting people at high risk and particularly at advanced age, cardiovascular and pulmonary disease. As cardiovascular patients are at high risk but also have dyspnea and fatigue as leading symptoms, prevention, diagnostics and treatment in these patients are important to provide adequate care for those with or without COVID-19 but most importantly when comorbid cardiovascular conditions are present. Severe COVID-19 with acute respiratory distress (ARDS) is challenging as patients with elevated myocardial markers such as troponin are at enhanced high risk for fatal outcomes. As angiotensin-converting enzyme 2 (ACE2) is regarded as the viral receptor for cell entry and as the Coronavirus is downregulating this enzyme, which provides cardiovascular and pulmonary protection, there is ongoing discussions on whether treatment with cardiovascular drugs, which upregulate the viral receptor ACE2 should be modified. As most of the COVID-19 patients have cardiovascular comorbidities like hypertension, diabetes, coronary artery disease and heart failure, which imposes a high risk on these patients, cardiovascular therapy should not be modified or even withdrawn. As cardiac injury is a common feature of COVID-19 associated ARDS and is linked with poor outcomes, swift diagnostic management and specialist care of cardiovascular patients in the area of COVID-19 is of particular importance and deserves special attention.","Clin Res Cardiol","Bohm, Michael","Frey, Norbert","Giannitsis, Evangelos","Sliwa, Karen","Zeiher, Andreas M","32462267"],"abstract":["Coronavirus diseases 2019 (COVID-19) has become a worldwide pandemic affecting people at high risk and particularly at advanced age, cardiovascular and pulmonary disease. As cardiovascular patients are at high risk but also have dyspnea and fatigue as leading symptoms, prevention, diagnostics and treatment in these patients are important to provide adequate care for those with or without COVID-19 but most importantly when comorbid cardiovascular conditions are present. Severe COVID-19 with acute respiratory distress (ARDS) is challenging as patients with elevated myocardial markers such as troponin are at enhanced high risk for fatal outcomes. As angiotensin-converting enzyme 2 (ACE2) is regarded as the viral receptor for cell entry and as the Coronavirus is downregulating this enzyme, which provides cardiovascular and pulmonary protection, there is ongoing discussions on whether treatment with cardiovascular drugs, which upregulate the viral receptor ACE2 should be modified. As most of the COVID-19 patients have cardiovascular comorbidities like hypertension, diabetes, coronary artery disease and heart failure, which imposes a high risk on these patients, cardiovascular therapy should not be modified or even withdrawn. As cardiac injury is a common feature of COVID-19 associated ARDS and is linked with poor outcomes, swift diagnostic management and specialist care of cardiovascular patients in the area of COVID-19 is of particular importance and deserves special attention."],"journal":"Clin Res Cardiol","authors":["Bohm, Michael","Frey, Norbert","Giannitsis, Evangelos","Sliwa, Karen","Zeiher, Andreas M"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462267","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s00392-020-01656-3","keywords":["corona","covid-19","cardiovascular risk","heart failure","hypertension","myocardial injury"],"topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1668079521332461569,"score":151.88872},{"pmid":32397803,"title":"Les liaisons dangereuses and the danger of deductions: The interplay between cardiovascular disease and COVID-19.","text":["Les liaisons dangereuses and the danger of deductions: The interplay between cardiovascular disease and COVID-19.","Eur J Prev Cardiol","Sciatti, Edoardo","Ceconi, Claudio","32397803"],"journal":"Eur J Prev Cardiol","authors":["Sciatti, Edoardo","Ceconi, Claudio"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32397803","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1177/2047487320925622","topics":["Prevention","Treatment"],"weight":1,"_version_":1666714494945984512,"score":149.45583}]}